122243-28-1

Basic information

• Product Name: 2-(4-broMophenyl)-1,1,1-trifluoropropan-2-ol
• Synonyms: 2-(4-broMophenyl)-1,1,1-trifluoropropan-2-ol;2-(4-Bromophenyl)-1,1,1-trifluoro-2-propanol
• CAS NO: 122243-28-1
• Molecular Formula: C₉H₈BrF₃O
• Molecular Weight: 269.0584296
• Mol File: 122243-28-1.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-broMophenyl)-1,1,1-trifluoropropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-broMophenyl)-1,1,1-trifluoropropan-2-ol(122243-28-1)
• EPA Substance Registry System: 2-(4-broMophenyl)-1,1,1-trifluoropropan-2-ol(122243-28-1)

Safety Data

• Hazardous Substances Data: 122243-28-1(Hazardous Substances Data)

Usage

Type of compound

Fluorinated alcohol

Functional groups

Trifluoromethyl group, bromine substituent, and hydroxyl group

Structure

A benzene ring with a trifluoromethyl group and a bromine substituent attached to it

Usage

Intermediate in the synthesis of pharmaceuticals and agrochemicals

Application

Building block in organic chemistry research for the production of various compounds

Unique features

Unique structure and reactivity leading to a wide range of applications in chemical and industrial processes

Upstream product

• 917-64-6 methyl magnesium iodide 
• 16184-89-7 4'-bromo-2,2,2-trifluoroacetophenone 
• 75-16-1 methylmagnesium bromide 
• 35739-70-9 dimethyldichlorotitanium(IV) 
• 75-46-7 trifluoromethan 
• 99-90-1 para-bromoacetophenone 
• 917-54-4 methyllithium 
• 106-37-6 1.4-dibromobenzene 
• 684-16-2 Hexafluoroacetone 
• 544-97-8 dimethyl zinc(II) 
• 18620-02-5 (4-bromophenyl)magnesium bromide 
• 421-50-1 1,1,1-trifluoro-2-propanone 

Downstream Products

• 1361216-31-0 tert-butyl (3S)-3-methyl-4-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl)-1-piperazinecarboxylate 
• 1361215-49-7 ((2R)-4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-phenyl)-2-piperazinyl)methyl methanesulfonate 
• 1361216-28-5 (2S)-1,1,1-trifluoro-2-(4-(4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361216-29-6 (2R)-1,1,1-trifluoro-2-(4-(4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361216-92-3 1,1,1-trifluoro-2-(4-(2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-02-8 (2S)-1,1,1-trifluoro-2-(4-((2R)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-00-6 (2R)-1,1,1-trifluoro-2-(4-((2R)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-03-9 (2S)-1,1,1-trifluoro-2-(4-((2S)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-01-7 (2R)-1,1,1-trifluoro-2-(4-((2S)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-05-1 (4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl)-2-piperazinyl)methyl methanesulfonate 
• 1361217-89-1 1,1,1-trifluoro-2-(4-(2-((3-pyridinylmethoxy)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-95-9 1,1,1-trifluoro-2-(4-(2-(4-morpholinylmethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-45-9 4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl)-2-piperazinecarbaldehyde 
• 1361218-40-7 1,1,1-trifluoro-2-(3-((3-methyl-3-oxetanyl)ethynyl)-4-(4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 

Relevant articles and documents

CRYSTAL POLYMORPHISM OF KCNQ2-5 CHANNEL ACTIVATOR

Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in t

KCNQ2-5 CHANNEL ACTIVATOR

The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 cha

Inhibition of hypoxia-induced gene transcription by substituted pyrazolyl oxadiazoles: Initial lead generation and structure-activity relationships

The transcription factors hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2) orchestrate a multitude of processes that allow tumor cells to survive under conditions of low oxygen and nutrients, and that lead to resistance to some apoptotic pathways and facilitate invasion and metastasis. Therefore, inhibition of transactivation by HIF has become an attractive target in cancer research. Herein we present the results of a cell-based screening approach that led to the discovery of substituted 1H-pyrazole-3-carboxamides. Chemical optimization of the hit class with respect to potency and metabolic stability is described; it resulted in novel 5-(1H-pyrazol-3-yl)-1,2,4-oxadiazoles that inhibit the hypoxia-induced accumulation of HIF-1α and HIF-2α. The HIF inhibitory potency in the screening cell system was improved from IC 50 190 to 0.7 nM, and significant parts of the SAR are disclosed. For a key compound, the ability to suppress the hypoxia-induced expression of HIF target genes was studied in A549 human lung adenocarcinoma cells. The same compound shows a favorable pharmacokinetic profile in rats after i.v. and p.o. administration. Suppressing HIF target genes: Substituted 5-(1H-pyrazol-3-yl)-1, 2,4-oxadiazoles are presented as a novel chemotype to specifically inhibit the hypoxia-induced transcription of target genes of the transcription factor hypoxia-inducible factor (HIF). The new chemotype was derived from 1H-pyrazole-3-carboxamides that had been discovered from a cell-based screen. We present the optimization of the potency and metabolic stability of the initial screening hit. Copyright